Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Interest Expenses (2016 - 2022)

PharmaCyte Biotech (PMCB) has disclosed Interest Expenses for 11 consecutive years, with -$1571.0 as the latest value for Q1 2022.

  • On a quarterly basis, Interest Expenses fell 730.92% to -$1571.0 in Q1 2022 year-over-year; TTM through Oct 2022 was -$1571.0, a 146.63% decrease, with the full-year FY2022 number at $509.0, down 83.29% from a year prior.
  • Interest Expenses was -$1571.0 for Q1 2022 at PharmaCyte Biotech, down from $1613.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1613.0 in Q4 2021 to a low of -$1571.0 in Q1 2022.
  • A 3-year average of $414.5 and a median of $460.0 in 2020 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: skyrocketed 138.26% in 2021, then crashed 730.92% in 2022.
  • PharmaCyte Biotech's Interest Expenses stood at $677.0 in 2020, then surged by 138.26% to $1613.0 in 2021, then tumbled by 197.4% to -$1571.0 in 2022.
  • Per Business Quant, the three most recent readings for PMCB's Interest Expenses are -$1571.0 (Q1 2022), $1613.0 (Q4 2021), and $467.0 (Q3 2021).